Topotecan
| Clinical data | |
|---|---|
| Trade names | Hycamtin, others | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a610007 | 
| License data | |
| Pregnancy category | 
 | 
| Routes of administration | Intravenous infusion, by mouth | 
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 31.4 % in humans | 
| Protein binding | 35% | 
| Metabolism | Liver | 
| Elimination half-life | 2–3 hours | 
| Excretion | Kidney | 
| Identifiers | |
| 
 | |
| CAS Number | 
 | 
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.213.372 | 
| Chemical and physical data | |
| Formula | C23H23N3O5 | 
| Molar mass | 421.453 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (what is this?) (verify) | |
Topotecan, sold under the brand name Hycamtin among others, is a chemotherapeutic agent medication that is a topoisomerase inhibitor. It is a synthetic, water-soluble analog of the natural chemical compound camptothecin. It is used in the form of its hydrochloride salt to treat ovarian cancer, lung cancer and other cancer types.
After GlaxoSmithKline received final FDA approval for topotecan on 15 October 2007, it became the first topoisomerase I inhibitor for oral use.